Latest News and Press Releases
Want to stay updated on the latest news?
-
Alvotech (NASDAQ: ALVO, ALVO-SDB) tilkynnti í dag að fyrirtækið afhent bréf til þátttakenda í lokuðu hlutafjárútboði sem fram fór þann 4. júní sl. Um 40 stofnanafjárfestar tóku þátt í útboðinu. Um 60%...
-
Alvotech (NASDAQ: ALVO, ALVO-SDB, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the...
-
Alvotech (NASDAQ: ALVO, ALVO-SDB, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the...
-
REYKJAVIK, Iceland, June 06, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
-
Alvotech (NASDAQ: ALVO) tekur þátt í árlegri heilbrigðisráðstefnu Goldman Sachs fjárfestingabankans sem haldin verður í Miami dagana 9.-11. júní nk. Fulltrúar félagsins funda með einstökum fjárfestum...
-
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Goldman Sachs...
-
HYDERABAD, India and REYKJAVIK, Iceland, June 05, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines...
-
Alvotech (NASDAQ: ALVO) tilkynnti í dag að fyrirtækið hefði gert samstarfssamning við Dr. Reddy’s Laboratories Ltd. (“Dr. Reddys”), alþjóðlegt lyfjafyrirtæki með höfuðstöðvar á Indlandi, um þróun,...
-
HYDERABAD, INDIA & REYKJAVIK, ICELAND (June 5, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
-
Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share